Poland Liver Cancer Therapeutics Market Report 2022 to 2030

Poland Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Poland Liver Cancer Therapeutics market will reach a value of $64.1 Mn from $17 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030. Liver Cancer Therapeutics in Poland is dominated by a few domestic pharmaceutical companies such as Polpharma Biologics, Adamed Group and Celon Pharma. The Liver Cancer Therapeutics market in Poland is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Poland Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10PLPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Dr. Vishwa Modhia

Buy Now

Poland Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Poland Liver Cancer Therapeutics market will reach a value of $64.1 Mn from $17 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030.

Poland is a high-income, developed country in Central Europe bordered by Belarus, the Czech Republic, Germany, Lithuania, Russia, Slovakia, and Ukraine. According to the latest WHO data published in 2020 Liver Cancer Deaths in Poland reached 2,290 or 0.64% of total deaths. The age-adjusted Death Rate is 3.10 per 100,000 population ranks Poland 162^nd in the world. Chronic hepatitis B or C infection, excessive alcohol intake, and non-alcoholic fatty liver disease (NAFLD) are all risk factors for liver cancer in Poland.

In comparison to other nations, the incidence of liver cancer in Poland is very low, with an estimated 4,000 new cases identified each year. However, liver cancer has a significant mortality rate, and it is estimated that it kills roughly 3,000 people in Poland each year. Poland’s government spent 6.5% of its GDP on healthcare in 2020.

Poland Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The Polish State Agency for the Prevention of Alcohol-Related Problems (PARPA) reports that the average Pole consumed more than 11 litres of pure alcohol in 2018. It reached 8 litres in 2000, demonstrating a significant growth from an already high level. HCC incidence has climbed by 50% in Poland's nearest neighbour, Germany, over the last 30 years. Poland's economy is broad, and it is near to Western European markets (agriculture, variety of industries, services). These aspects could boost Poland Liver Cancer Therapeutics market.

Market Restraints

Hepatocellular carcinoma occurrence in Poland is comparable to the rest of Europe and is increasing. The incidence rate is significantly understated. It is the result of poor epidemiological data collection practices. Men over the age of 50 with concurrent liver cirrhosis are the most at risk. HCV infection is the most common cause of HCC. According to WHO data, Poland, Western Europe, the United States, and Australia have a low HCC incidence rate ranging from 2.5 to 4.9 per 100,000 people. Cholangiocellular carcinoma accounts for 10% or less of primary liver cancer in most countries. Poland, in general, does not spend on R&D and imports a substantial amount of its exports. These factors may deter new entrants into the Poland Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Polpharma Biologics: This is a Polish biotechnology company that specializes in the development and production of biosimilars. The company has a number of products in development for the treatment of cancer, including liver cancer
Adamed Group: This is a Polish pharmaceutical company that develops and produces a range of prescription drugs and over-the-counter medicines
Celon Pharma: This is a Polish biopharmaceutical company that specializes in the development of innovative drugs for the treatment of cancer and other diseases
Genexo
OncoArendi Therapeutics

Healthcare Policies and Reimbursement Scenarios

In Poland, liver cancer is regulated and treated according to the guidelines set forth by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). In terms of reimbursement, the National Health Fund (NFZ) is the main payer for healthcare services and medications in Poland. The level of reimbursement for liver cancer treatment may depend on factors such as the type of treatment, the patient's health insurance coverage, and the availability of alternative treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.